Feed BMYMP
BM

Bristol-Myers Squibb Company PFD CONV 2 BMYMP · OTC

$400.00 -57.46% (-$540.22)

Summary

55 / 100 · Bulios Score

What speaks for it

  • Revenue grew by 21% a year over the last 3 years.
  • It earns 90 USD a year on every 100 USD of invested capital.
  • Out of every 100 USD of revenue, 15 USD is left as net profit.
  • The share price is below the Bulios Fair Price.

What to watch

  • For every 100 USD of shareholders' equity it carries -81 USD of debt.
  • Earnings per share swing sharply from year to year.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price $400
P/E today 115.9
Drug Manufacturers - General industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 115.9 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

Revenue (USD)

  • Analyst estimate

Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 21% a year. Earnings per share grew by 14% a year over the last 3 years.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Yes

It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

Small, safe
Yield
0.38%
Paid out of profit
43%

You receive $1.00 per share a year. The company covers the payout with ease.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

50% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

This revenue breakdown is on the way.

By region

This revenue breakdown is on the way.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.